ENDRA Life Sciences to Report Third Quarter 2021 Financial Results on November 15, 2021

Rhea-AI Summary

ENDRA Life Sciences Inc. (NASDAQ: NDRA) will announce its third-quarter financial results on November 15, 2021, after the market close. Following the release, management will conduct a conference call at 4:30 p.m. Eastern Time to discuss results and recent developments. Investors can pre-register for the call or access a webcast via the company's Investor Relations page. ENDRA specializes in Thermo Acoustic Enhanced UltraSound (TAEUS), aiming to provide cost-effective diagnostic imaging, particularly for liver conditions affecting over one billion people globally.

ANN ARBOR, Mich.--(BUSINESS WIRE)-- ENDRA Life Sciences Inc. (ENDRA) (NASDAQ: NDRA), a pioneer of enhanced ultrasound technologies, today announced that the company will report financial results for the third quarter of 2021 on Monday, November 15, 2021 after the close of trading on the U.S. financial markets. Management will host a conference call and webcast beginning at 4:30 p.m. Eastern time to discuss the results, provide an update on recent corporate developments and answer questions.

Participants are encouraged to pre-register for the conference call using this link. Callers who pre-register will be given a unique PIN to gain immediate access to the call and bypass the live operator. Participants may register at any time, including up to and after the call start time. A webcast of the call may also be accessed at ENDRA’s Investor Relations page and here. Those without internet access or unable to pre-register may dial in by calling (866) 777-2509 (U.S.) or (412) 317-5413 (International).

A replay of the webcast will be available beginning approximately one hour after the completion of the live conference call here. A dial-in replay of the call will be available until November 22, 2021 by calling (877) 344-7529 (U.S.) or (412) 317-0088 (International) and providing the passcode 10161144.

About ENDRA Life Sciences Inc.

ENDRA Life Sciences is the pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS^®), a ground-breaking technology being developed to visualize tissue like MRI, but at 1/50th the cost and at the point of patient care. TAEUS^® is designed to work in concert with 400,000 cart-based ultrasound systems in use globally today. TAEUS^® is initially focused on the measurement of fat in the liver as a means to assess and monitor Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH), chronic liver conditions that affect over one billion people globally, and for which there are no practical diagnostic tools. Beyond the liver, ENDRA is exploring several other clinical applications of TAEUS^®, including visualization of tissue temperature during energy-based surgical procedures. For more information, please visit www.endrainc.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211108005082/en/

Company Contact:

Irina Pestrikova

Senior Director, Finance

investors@endrainc.com

www.endrainc.com

Investor Relations Contact:

Yvonne Briggs

LHA Investor Relations

(310) 691-7100

ybriggs@lhai.com

Source: ENDRA Life Sciences Inc.

FAQ

When will ENDRA Life Sciences report its financial results?

ENDRA Life Sciences will report its financial results for the third quarter of 2021 on November 15, 2021, after the market close.

What time is the conference call for ENDRA Life Sciences' financial results?

The conference call will start at 4:30 p.m. Eastern Time on November 15, 2021.

How can I access the webcast for ENDRA Life Sciences' conference call?

You can access the webcast for ENDRA's conference call on their Investor Relations page.

What technology does ENDRA Life Sciences focus on?

ENDRA Life Sciences focuses on Thermo Acoustic Enhanced UltraSound (TAEUS), a technology designed to visualize tissues at a lower cost compared to MRI.